

FINANCIAL TEAR SHEET


Corporate Profile

We are a clinical stage biopharmaceutical company focused on developing innovative therapeutics to improve the lives of patients with neurological disorders. Building upon our extensive knowledge of human genetics and diseases caused by mutations in ion channels, known as channelopathies, we are advancing – both independently and with our collaborators – a novel product pipeline of central nervous system, or CNS, therapies to address areas of high unmet medical need, such as epilepsy, migraine, and pain.

Stock Performance

XENE (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$8.08
Change (%)	▲ 0.06 (0.75%)
Volume	75,135
52 Week Low	\$3.55
Market Cap	\$203,942,012
Rolling EPS	-1.80
PE Ratio	0
Shares Outstanding	25,240,348



Data as of 02/15/19 4:00 p.m. ET

Recent Press Releases & Upcoming Events

January 28, 2019 - [Xenon Provides Key Regulatory Updates on XEN007 and XEN1101](#)

There are currently no events scheduled.

January 6, 2019 - [Xenon Pharmaceuticals Outlines 2019 Key Milestones](#)

December 3, 2018 - [Xenon Announces Final Results of XEN1101 Phase 1 Clinical Trial and Update on XEN901 Phase 1 Clinical Trial at the American Epilepsy Society \(AES\) Annual Meeting](#)

SEC Filings

Filing Date	Form
02/14/19	SC 13G/A
02/14/19	SC 13G/A
02/14/19	SC 13G
02/14/19	SC 13G

Corporate Governance

[Simon Pimstone, MBChB, Ph.D., FRCPC](#)

[Ian Mortimer, MBA, CPA, CMA](#)

[Ernesto Aycardi, M.D.](#)

[Robin Sherrington, Ph.D.](#)

[James Empfield, Ph.D.](#)

[Charles Cohen, PhD](#)

[Jodi Regts, BA, MBA](#)

Data provided by Nasdaq. Minimum 15 minutes delayed. [View Attributions and Sources](#)